Research shows potential benefit of testosterone therapy for older women

Researchers say the findings warrant further research into the potential benefits of testosterone therapies for older women.

Before menopause, women's ovaries are the primary source of testosterone circulating in the blood. After menopause, because the ovaries stop functioning, blood testosterone is made from the hormone DHEA which comes from adrenal glands.

Blood testosterone levels decrease with age in women from their early 20s but do not change significantly as a result of natural menopause. However, after the age of 70 years, women have blood testosterone levels similar to those seen in young premenopausal women.

Using data captured in the longitudinal ASPREE (ASPirin in Reducing Events in the Elderly) randomised trial, this study, led by Susan Davis, Professor of women's health in the Monash School of Public Health and Preventive Medicine, measured blood testosterone, DHEA and oestrogen concentrations in women over 70 with no prior CVD events. Women who had low blood testosterone and DHEA concentrations but not low estrogen, had twice the risk of a cardiovascular event than women with higher testosterone blood levels.

"We have shown in past studies that testosterone therapy lowers blood pressure and increases blood flow in arteries. So our hypothesis was that having higher testosterone may protect older women from cardiovascular disease, which is contrary to the conventional belief that testosterone is bad for the cardiovascular system," Professor Davis said.

"We need to stop thinking about testosterone as a 'male' hormone that is bad for women. It is an important human hormone for both women and men.

"Further research is needed to better understand testosterone action in blood vessels and the heart, including whether treating postmenopausal women with low testosterone protects against cardiovascular disease."

The Sex Hormones in Older Women (SHOW) study incorporated results from 9180 Australian women, aged at least 70 years, with no prior CVD events of which 5535 were included in this analysis with a median age of 74 years.

The findings are now published in The Lancet Healthy Longevity journal.